ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,291.34
0.15%
Dow Jones
38,711.29
0.36%
US Dollar vs MXN
17.77122
-0.25%
Brent Oil
77.485
0.49%
Bitcoin
71,084.51
0.74%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Cadrenal Therapeutics Inc (CVKD)

  7. Cadrenal Therapeutics Inc (CVKD) Noticias

CVKD Cadrenal Therapeutics Inc

0.4605
-0.0365 (-7.34%)
04 Jun 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Cadrenal Therapeutics Inc CVKD NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
-0.0365 -7.34% 0.4605 17:35:55
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.495 0.4607 0.495 0.48 0.497
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
03/6/202408:00PRNUSCadrenal Therapeutics Highlights Presentation of New Trial..
29/5/202416:27EDGAR2Form PRE 14A - Other preliminary proxy statements
23/5/202408:00PRNUSCadrenal Therapeutics to Participate in the Lytham Partners..
09/5/202408:00PRNUSCadrenal Therapeutics Provides First Quarter 2024 Corporate..
09/5/202405:23EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/4/202415:30PRNUSCadrenal Therapeutics to Participate in Noble Capital..
09/4/202408:00PRNUSCadrenal Therapeutics Receives FDA Orphan Drug Designation..
11/3/202408:15EDGAR2Form 8-K - Current report
11/3/202408:00PRNUSCadrenal Therapeutics Provides Fourth Quarter 2023 Corporate..
05/3/202416:24EDGAR2Form 8-K - Current report
26/2/202408:00PRNUSCadrenal Therapeutics to Participate at Technology and Heart..
15/2/202407:00EDGAR2Form 8-K/A - Current report: [Amend]
12/2/202415:49EDGAR2Form 8-K - Current report
08/2/202408:00PRNUSCadrenal Therapeutics Appoints Jeff Cole as Chief Operating..
31/1/202408:00PRNUSCadrenal Therapeutics Highlights Publication of..
24/1/202408:00PRNUSCadrenal Therapeutics to Participate in a Fireside Chat at..
04/1/202408:00PRNUSCadrenal Therapeutics to Present at the Biotech Showcase on..
19/12/202308:00PRNUSNoble Capital Markets Initiates Coverage on Cadrenal..
12/12/202308:00PRNUSCadrenal Therapeutics Engages The Sage Group to Advance..
30/11/202315:15PRNUSCadrenal Therapeutics to Present at the NobleCon 19..
09/11/202308:15EDGAR2Form 8-K - Current report
09/11/202308:00PRNUSCadrenal Therapeutics Provides Third Quarter 2023 Corporate..
09/11/202307:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
23/10/202316:04EDGAR2Form 8-K - Current report
09/10/202315:15PRNUSCadrenal Therapeutics to Participate in the Lytham Partners..
08/9/202315:10EDGAR2Form 8-K - Current report
05/9/202307:00PRNUSCadrenal Therapeutics Highlights Additional Need for a New..
31/8/202315:05EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
31/8/202315:05EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
30/8/202307:00PRNUSCadrenal Therapeutics Expands Evaluation of Tecarfarin for..
28/8/202315:58EDGAR2Form ARS - Annual Report to Security Holders
28/8/202315:55EDGAR2Form DEF 14A - Other definitive proxy statements
28/8/202315:15PRNUSCadrenal Therapeutics to Participate in the H.C. Wainwright..
18/8/202305:06EDGAR2Form 8-K - Current report
16/8/202315:10EDGAR2Form 8-K - Current report
16/8/202315:05EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
10/8/202308:16EDGAR2Form 8-K - Current report
10/8/202308:00PRNUSCadrenal Therapeutics Provides Second Quarter 2023 Corporate..
10/8/202305:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/8/202308:00PRNUSCadrenal Therapeutics Expands Focus for Tecarfarin to..
01/8/202305:06EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
24/7/202308:20EDGAR2Form 8-K - Current report
24/7/202308:15EDGAR2Form S-1 - General form for registration of securities under..
24/7/202308:00PRNUSCadrenal Therapeutics Announces Appointment of Robert..
14/7/202315:52EDGAR2Form 8-K - Current report
14/7/202314:02PRNUSCadrenal Therapeutics Announces Closing of $7.5 Million..
12/7/202314:17PRNUSCadrenal Therapeutics Announces $7.5 Million Private..

Su Consulta Reciente

NASDAQ
CVKD
Cadrenal Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados